165 related articles for article (PubMed ID: 37405498)
1. A novel TREM1/DAP12-based multiple chain CAR-T cell targets PTK7 in ovarian cancer therapy.
Xu T; Wang C; Wang X; Wang E; Wang B; Sun M
Med Oncol; 2023 Jul; 40(8):226. PubMed ID: 37405498
[TBL] [Abstract][Full Text] [Related]
2. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
3. TREM1/Dap12-based CAR-T cells show potent antitumor activity.
Chen B; Zhou M; Zhang H; Wang C; Hu X; Wang B; Wang E
Immunotherapy; 2019 Aug; 11(12):1043-1055. PubMed ID: 31268375
[No Abstract] [Full Text] [Related]
4. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
[TBL] [Abstract][Full Text] [Related]
6. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.
Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M
Immunology; 2024 Mar; ():. PubMed ID: 38469682
[TBL] [Abstract][Full Text] [Related]
7. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer.
Leong L; Tan HL; Cua S; Yong KSM; Chen Q; Choo A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936170
[TBL] [Abstract][Full Text] [Related]
10. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model.
Fu J; Shang Y; Qian Z; Hou J; Yan F; Liu G; Dehua L; Tian X
J Vet Med Sci; 2021 Mar; 83(2):241-247. PubMed ID: 33328392
[TBL] [Abstract][Full Text] [Related]
12. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
13. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
[TBL] [Abstract][Full Text] [Related]
14. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
[TBL] [Abstract][Full Text] [Related]
15. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
16. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
18. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model.
Monzo HJ; Kalander K; Hyytiäinen MM; Elbasani E; Wall J; Moyano-Galceran L; Tanjore Ramanathan J; Jukonen J; Laakkonen P; Ristimäki A; Carlson JW; Lehti K; Salehi S; Puolakkainen P; Haglund C; Seppänen H; Leppä S; Ojala PM
Mol Cancer Ther; 2023 Nov; 22(11):1319-1331. PubMed ID: 37486980
[TBL] [Abstract][Full Text] [Related]
20. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
